BioMarin Pharmaceutical (BMRN) reported Wednesday that its trial for Palynziq in adolescents with phenylketonuria showed a significant reduction in blood phenylalanine levels in patients aged 12 to 17.
The study met its primary efficacy endpoint, demonstrating that Palynziq was more effective than diet alone in lowering blood Phe levels. The safety results were consistent with the known profile of the medicine.
The company plans to present detailed findings at an upcoming medical meeting and will seek regulatory approval later this year to expand Palynziq's label for adolescent use.
Price: 68.00, Change: +0.06, Percent Change: +0.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.